Targets › RDRP
5 programs from 4 companies in 16 trials: 10 Phase 2, 3 Phase 3, 2 Phase 1, 1 Phase 4; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on RDRP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Simcere Pharmaceutical Co., Ltd | SIM0916 (Deuremidevir Hydrobromide) RSV RNA-dependent RNA polymerase inhibitor | RDRP | Phase 3 | Respiratory Syncytial Virus Infection | Mar 2027 |
| Pfizer | Remdesivir RNA-directed RNA polymerase L inhibitor; Replicase polyprotein 1ab inhibitor | 3C, RDRP | Phase 3 | COVID-19 Infection; SARS CoV-2 Post-Acute Sequelae; COVID-19; COVID - 19 … | Sep 2027 |
| Merck & Co. (MSD) | Molnupiravir (MK-4482, LAGEVRIO®) Nucleoside analog inhibitor of viral RNA-dependent RNA polymerase (RdRp) | RDRP | Phase 3 | Coronavirus Disease (COVID-19); Respiratory Syncytial Virus; COVID-19; Dengue | Jan 2031 |
| University of Liverpool | EIDD-2801 (also: MK-4482, Molnupiravir) Nucleoside analog RNA polymerase inhibitor | RDRP | Phase 1 | Covid19 | Mar 2027 |
| University of Liverpool | Favipiravir RNA-directed RNA polymerase inhibitor | RDRP | Phase 1 | Covid19 | Mar 2027 |
COVID-19 (4) Dengue (2) Covid19 (2) COVID-19 Infection (1) SARS CoV-2 Post-Acute Sequelae (1) COVID - 19 (1) Respiratory Syncytial Virus (RSV) (1) Hematopoietic and Lymphatic System Neoplasm (1) Respiratory Syncytial Virus Infection (1) Coronavirus Disease (COVID-19) (1) Respiratory Syncytial Virus (1)
small molecule (3), mixed (2)
University of Liverpool (2) Pfizer (1) Simcere Pharmaceutical Co., Ltd (1) Merck & Co. (MSD) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.